Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 24, showing 10 Applications out of 238 total, starting on record 41, ending on 50

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

41.

ECCT/25/03/07   Sparkle - Site 1405
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. Gertrudes Children’s Hospital (Nairobi City county)
6. Victoria Biomedical Research Institute (Kisumu county)
 
16-09-2025 View

42.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
14-07-2025 View

43.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
20-05-2025 View

44.

ECCT/24/11/01   Sparkle
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Site 1401:Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402:Ahero Clinical trials Unit (Kisumu county)
3. Site 1403:International Cancer institute (Uasin Gishu county)
4. Site 1404:Kondele Childrens Hospital (Kisumu county)
5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county)
6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county)
 
13-05-2025 View

45.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
30-04-2025 View

46.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
24-04-2025 View

47.

ECCT/24/09/01   L9LS-PD
    Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd)   
Principal Investigator(s)
1. Mary Iwaret Otiti
Site(s) in Kenya
1. Homa Bay County Teaching and Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
 
16-03-2025 View

48.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
06-02-2025 View

49.

ECCT/24/08/06   KALUMA Study
    A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment    
Principal Investigator(s)
1. Dr Patricia Odera Ojwang
2. Dr. Bernhards Ogutu
3. Dr.Bernhards Ogutu
Site(s) in Kenya
1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county)
2. Site 1601:Kombewa Clinical Research Centre (Kisumu county)
3. Ahero Clinical Trial Unit (Kisumu county)
 
26-01-2025 View

50.

ECCT/24/08/03   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Mary Inziani Matilu
Site(s) in Kenya
1. KEMRI-Mtwapa Clinical Annex (Kilifi county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. University of Nairobi Clinical Research Centre (Nairobi City county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
21-12-2024 View